A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node—ablated, His bundle-paced dog

Antzelevitch, 2004, Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem?, Journal of Electrocardiology, 37, 15, 10.1016/j.jelectrocard.2004.08.004 Aytemir, 1999, Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms, Pacing and Clinical Electrophysiology, 22, 1397, 10.1111/j.1540-8159.1999.tb00635.x Bexton, 1986, Diurnal variation of the QT interval—influence of the autonomic nervous system, British Heart Journal, 55, 253, 10.1136/hrt.55.3.253 Chiladakis, 1998, Idiopathic long QT syndrome with late onset of bradycardia-dependent and short-coupled variant of torsade de pointes, International Journal of Cardiology, 64, 93, 10.1016/S0167-5273(97)00331-8 Fossa, 2002, The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT–RR interval assessment, Journal of Pharmacology and Experimental Therapeutics, 202, 828, 10.1124/jpet.102.035220 Fossa, 2004, Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig, European Journal of Pharmacology, 486, 209, 10.1016/j.ejphar.2003.12.028 Fujiki, 1994, Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias, Journal of Cardiovascular Pharmacology, 23, 374, 10.1097/00005344-199423030-00003 Gladziwa, 1991, Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis, Clinical Pharmacology and Therapeutics, 50, 673, 10.1038/clpt.1991.206 Gras, 1999, Effects of H1 antihistamines on animal models of QTc prolongation, Drug Safety, 21, 39, 10.2165/00002018-199921001-00006 Holford, 1981, The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: Concentration—effects relationships, British Journal of Clinical Pharmacology, 11, 187, 10.1111/j.1365-2125.1981.tb01123.x Hondeghem, 2001, Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic, Circulation, 103, 2004, 10.1161/01.CIR.103.15.2004 Honig, 1993, Terfenadine–ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences, Journal of the American Medical Association, 269, 1513, 10.1001/jama.1993.03500120051025 Huang, 1992, Heart rate—QT relationships during baroreceptor stimulation with diminished autonomic influence on the ventricles, Integrative Physiological and Behavioral Science, 27, 6, 10.1007/BF02691087 Khan, 2004, Brugada and long QT-3 syndromes: Two phenotypes of the sodium channel disease, Annals of Noninvasive Electrocardiology, 9, 280, 10.1111/j.1542-474X.2004.93533.x Lainee, 1998, Electrocardiographic effects of mizolastine and terfenadine in conscious dogs, Japanese Pharmacology & Therapeutics, 26, S807 Magnano, 2002, Autonomic nervous system influences on QT interval in normal subjects, Journal of the American College of Cardiology, 39, 1820, 10.1016/S0735-1097(02)01852-1 Malik, 2001, Problems of heart rate correction in assessment of drug-induced QT interval prolongation, Journal of Cardiovascular Electrophysiology, 12, 411, 10.1046/j.1540-8167.2001.00411.x Malik, 2002, The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes, Pacing and Clinical Electrophysiology, 25, 209, 10.1046/j.1460-9592.2002.00209.x McTavish, 1990, Terfenadine—An updated review of its pharmacological properties and therapeutic efficacy, Drugs, 39, 552, 10.2165/00003495-199039040-00006 Michalets, 2000, Drug interactions with cisapride. Clinical implications, Clinical Pharmacokinetics, 39, 49, 10.2165/00003088-200039010-00004 Minematsu, 2001, Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: Pharmacodynamic model incorporating a site of adverse effect, Journal of Pharmacokinetics and Pharmacodynamics, 6, 533, 10.1023/A:1014460404352 Ming, 1995, Terfenadine blocks time-dependent Ca2+, Na+ and K+ channels in guinea pig ventricular myocytes, Journal of Cardiovascular Pharmacology, 26, 761, 10.1097/00005344-199511000-00013 Olivier, 2003, Atrioventricular nodal ablation and His-Bundle pacing: An acute model for proarrhythmic risk assessment, Journal of Cardiovascular Electrophysiology, 14, 1356, 10.1046/j.1540-8167.2003.03215.x Oto, 2001, 151 Redfern, 2003, Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development, Cardiovascular Research, 58, 32, 10.1016/S0008-6363(02)00846-5 Redfern, 2002, Safety pharmacology—A progressive approach, Fundamental and Clinical Pharmacology, 16, 161, 10.1046/j.1472-8206.2002.00098.x Roden, 2004, Drug-induced prolongation of the QT interval, The New England Journal of Medicine, 350, 1013, 10.1056/NEJMra032426 Sanders, 2004, Stability of ventricular repolarization in conscious dogs with chronic atrioventricular dissociation and His-Bundle pacing, Pacing and Clinical Electrophysiology, 27, 1475, 10.1111/j.1540-8159.2004.00664.x Usui, 1998, Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model, Heart and Vessels, 13, 49, 10.1007/BF01744586 Van Haarst, 1998, The influence of cisapride and clarithromycin on QT intervals in healthy volunteers, Clinical Pharmacology and Therapeutics, 64, 542, 10.1016/S0009-9236(98)90137-0 Webster, 2001, Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog, Xenobiotica, 31, 633, 10.1080/00498250110054632 Yelamanchi, 2001, Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography, American Journal of Therapeutics, 8, 117, 10.1097/00045391-200103000-00006